Charles River Laboratories Announces Fourth-Quarter and Full-Year 2016 Results from Continuing Operations and Provides 2017 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to Charles River Laboratories Announces Fourth-Quarter and Full-Year 2016 Results from Continuing Operations and Provides 2017 Guidance

Charles River Labs (CRL) PT Raised to $84 at UBS Following Strong 4Q Results

February 15, 2017 9:31 AM EST

UBS analyst Jonathan Groberg maintains Sell rating and raises price target on Charles River Laboratories International (NYSE: CRL) to $84 (from $78), as the company announced revenue and EPS figures above consensus projections.

Groberg comments, "CRL reported 4Q16 results with reported revenue of $467m,... More

Charles River Labs (CRL) PT Raised to $104 at Jefferies Following Strong 4Q Results

February 15, 2017 8:11 AM EST

Jefferies analyst David Windley reiterates Buy rating and raises price target on Charles River Laboratories (NYSE: CRL), as the company reported 2016 fourth quarter revenue and EPS above consensus.

Windley comments, "4Q results far outpaced consensus revenue/EPS driven by strength across the 3 segments.... More

Charles River Laboratories (CRL) Tops Q4 EPS by 10c, Guides FY17 EPS In-Line

February 14, 2017 6:33 AM EST

Charles River Laboratories (NYSE: CRL) reported Q4 EPS of $1.21, $0.10 better than the analyst estimate of $1.11. Revenue for the quarter came in at $466.8 million versus the consensus estimate of $441.64 million.

GUIDANCE:

Charles River Laboratories sees FY2017 EPS of $5.00-$5.10, versus the... More